PRESS-RELEASE filed May 14, 2026 at 08:00 ET
Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% below the $1.7M estimate. The net loss of $23.7M compares to net income of $148.5M in Q1 2025, driven by the absence of Takeda license revenue and reduced R&D spend. Cash runway extends into H1 2028, but the revenue collapse and EPS miss signal a pre-commercial biotech with no near-term catalysts beyond Takeda's Phase 3 plans.